Avidity Biosciences Inc (RNA) concluded trading on Wednesday at a closing price of $31.27, with 4.82 million shares of worth about $150.67 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 2.52% during that period and on July 09, 2025 the price saw a gain of about 6.91%. Currently the company’s common shares owned by public are about 120.51M shares, out of which, 109.84M shares are available for trading.
Stock saw a price change of 9.87% in past 5 days and over the past one month there was a price change of -13.71%. Year-to-date (YTD), RNA shares are showing a performance of -19.82% which increased to 7.53% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $21.51 but also hit the highest price of $56.00 during that period. The average intraday trading volume for Avidity Biosciences Inc shares is 1.39 million. The stock is currently trading 4.33% above its 20-day simple moving average (SMA20), while that difference is up 2.02% for SMA50 and it goes to -9.64% lower than SMA200.
Avidity Biosciences Inc (NASDAQ: RNA) currently have 120.51M outstanding shares and institutions hold larger chunk of about 107.70% of that.
The stock has a current market capitalization of $3.77B and its 3Y-monthly beta is at 0.93. It has posted earnings per share of -$3.01 in the same period. It has Quick Ratio of 16.91 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RNA, volatility over the week remained 4.65% while standing at 5.57% over the month.
Analysts are in expectations that Avidity Biosciences Inc (RNA) stock would likely to be making an EPS of -0.95 in the current quarter, while forecast for next quarter EPS is -1.02 and it is -4.39 for next year. For the current quarter EPS, analysts have given the company a lowest target -1.33 which is -0.55 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.65 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -36.11% while it is estimated to decrease by -11.63% in next year. EPS is likely to grow at an annualized rate of -4.03% for next 5-years, compared to annual growth of -34.37% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Bernstein on June 24, 2025 offering an Outperform rating for the stock and assigned a target price of $50 to it. Coverage by Wolfe Research stated Avidity Biosciences Inc (RNA) stock as an Outperform in their note to investors on June 17, 2025, suggesting a price target of $55 for the stock. On June 11, 2025, Raymond James Initiated their recommendations, while on March 13, 2025, Citigroup Initiated their ratings for the stock with a price target of $70. Stock get an Outperform rating from BMO Capital Markets on March 12, 2025.
